Sign up to save your podcasts
Or
Share ESMO 2022: PATHFINDER Presents Screening Paradigm Shift with A Blood Test to Facilitate Early Detection
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ESMO 2022: PATHFINDER Presents Screening Paradigm Shift with A Blood Test to Facilitate Early Detection
The availability of a blood test for circulating DNA that can be used widely in healthy individuals to check for molecular signs of multiple cancers led Deb Schrag, MD, MPH, formerly of the Dana-Farber Cancer Center in Boston and currently Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, to research it's use as a means of spotting a wide range of cancers early—including types for which there is currently no routine screening (Abstract 903O). At the European Society for Medical Oncology 2022 Annual Congress, she told OncTimes Talk reporter Peter Goodwin about the findings which give her confidence that widespread blood testing could play an important role in the overall battle against cancer.
View all episodes
By Oncology TimesThe availability of a blood test for circulating DNA that can be used widely in healthy individuals to check for molecular signs of multiple cancers led Deb Schrag, MD, MPH, formerly of the Dana-Farber Cancer Center in Boston and currently Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, to research it's use as a means of spotting a wide range of cancers early—including types for which there is currently no routine screening (Abstract 903O). At the European Society for Medical Oncology 2022 Annual Congress, she told OncTimes Talk reporter Peter Goodwin about the findings which give her confidence that widespread blood testing could play an important role in the overall battle against cancer.